<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646917</url>
  </required_header>
  <id_info>
    <org_study_id>Bellmed001</org_study_id>
    <nct_id>NCT02646917</nct_id>
  </id_info>
  <brief_title>SkinPen Efficacy on Acne Scars on the Face and/or Back</brief_title>
  <official_title>A Single-Center Trial to Evaluate the Efficacy and Tolerability of SkinPen on Male and Female Subjects' Acne Scars on the Face and/or Back</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellus Medical, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center, clinical trial will take place over a 90 day course followed by 1-month&#xD;
      and 6-month post treatment visits to assess the efficacy and tolerability of the SkinPen&#xD;
      device when used on both men and women on the face and/or back.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At least 20 subjects of varying Fitzpatrick skin types will be admitted to the trial for&#xD;
      treatment on their moderate to severe acne scars on the face and/or back. Implementation of&#xD;
      needle depths ranging from 0.25 mm to 2.0 mm will depend on severity of scars and their&#xD;
      location. Each subject will undergo 3 treatments in 30 day increments and will take&#xD;
      pre-treatment images as well as 1-month and 6-months post treatment images. Assessment will&#xD;
      be based on the Goodman and Baron's grading system, the Clinician's Global Aesthetic&#xD;
      Improvement Scale, as well as a self-assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">July 25, 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Acne Scars</measure>
    <time_frame>Baseline, 1 month post treatment, and 6 months post treatment</time_frame>
    <description>Goodman and Baron's Qualitative grading system. Possible scores range from 1 = mild to 4 = severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician's Global Aesthetic Improvement Assessment (CGAIS)</measure>
    <time_frame>1 month post treatment, and 6 months post treatment</time_frame>
    <description>Clinician's Global Aesthetic Improvement Assessment:&#xD;
minimal score is 1- Very much improved and, maximum score is 5 -Worse: The appearance is worse than the original condition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Photo Grading of Acne Scar Assessment</measure>
    <time_frame>Day 1 (Baseline), Day 30, Day 60, 1-Month post treatment and 6 Month post treatment</time_frame>
    <description>Photo grading of acne scars assessment was done using the following scale [Karnik J. et al, JAAD 2014, 71 (1)]:&#xD;
Grade- Term- Description&#xD;
0 - Clear-- No depression is seen in the treatment area. Macular discoloration may be seen.&#xD;
- Very mild- - A single depression is easily noticeable with direct lighting (deep). Most or all of the depressions seen are only readily apparent with tangential lighting (shallow).&#xD;
- Mild-- A few to several, but less than half of all the depressions are easily noticeable with direct lighting(deep). Most of the depressions see are only readily apparent with tangential lighting (Shallow)&#xD;
3- Moderate-- More than half of the depressions are apparent with direct lighting (deep)&#xD;
4- Severe-- All or almost all the lesions can be seen with direct lighting (deep)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Self-Assessment Using SASIS</measure>
    <time_frame>One Month Post Treatment, 6 Month Post Treatment</time_frame>
    <description>Subject self-assessment was completed in 2 steps for self-assessed scar improvement scale (SASIS) and subject global aesthetic improvement scale (SGAIS):&#xD;
Based on a live assessment (subjects were provided with a hand mirror for assessment) of the subject while referring to pre-treatment images.&#xD;
Based on a comparison of pre-treatment images to current post-treatment images. Rating of Acne Scars&#xD;
1-Exacerbation of acne scars 0 No change in the appearance of acne scars&#xD;
1% - 25% improvement in the appearance of acne scars&#xD;
25% - 50% improvement in the appearance of acne scars 3-50% - 75% improvement in the appearance of acne scars 4-75% - 99% improvement in the appearance of acne scars</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Self-Assessment Using Global Aesthetic Improvement Scale (SGAIS)</measure>
    <time_frame>1-Month Post Treatment and 6- Month Post Treatment</time_frame>
    <description>The following rating scale was used for SGAIS:&#xD;
Rating and Description&#xD;
- Very much improved: Optimal cosmetic result&#xD;
- Much improved: Marked improvement in appearance from the initial condition, but not completely optimal&#xD;
- Improved: Obvious improvement in appearance from initial condition&#xD;
-No change: The appearance is essentially the same as the original condition&#xD;
- Worse: The appearance is worse than the original condition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Atrophic Acne Scar</condition>
  <arm_group>
    <arm_group_label>SkinPen II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three treatments using SkinPen II aesthetic microneedling device to each patient, with each treatment spaced one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SkinPen Precision</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three treatments using SkinPen Precision aesthetic microneedling device to each patient, with each treatment spaced one month apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aesthetic Microneedling Treatment</intervention_name>
    <description>Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
    <arm_group_label>SkinPen II</arm_group_label>
    <arm_group_label>SkinPen Precision</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women 18 to 60 years of age.&#xD;
&#xD;
          -  Subjects in good health.&#xD;
&#xD;
          -  Approximately 5 to 10 atrophic acne scars of mixed types (boxcar and/or rolling scars&#xD;
             with some icepick scars allowed) on face and/or back that are moderate to severe.&#xD;
&#xD;
          -  Desire correction of his/her acne scarring.&#xD;
&#xD;
          -  Subjects of child bearing potential must take a urine pregnancy test and must test&#xD;
             negative.&#xD;
&#xD;
          -  Subjects willing to sign a photography release.&#xD;
&#xD;
          -  Willingness to cooperate and participate by following study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergies to facial or general skin care products&#xD;
&#xD;
          -  Presence of an active systemic or local skin disease.&#xD;
&#xD;
          -  Severe solar elastosis.&#xD;
&#xD;
          -  Sensitivity to topical lidocaine.&#xD;
&#xD;
          -  Recent history of significant trauma to the face (&lt; 6 months).&#xD;
&#xD;
          -  Significant scarring other than acne scars in treated area(s).&#xD;
&#xD;
          -  Severe of cystic active and clinically significant acne on the area(s) to be treated.&#xD;
&#xD;
          -  History of systemic granulomatous diseases.&#xD;
&#xD;
          -  History of hypertrophic or keloid scars.&#xD;
&#xD;
          -  Current cancerous or pre-cancerous lesions in area(s) to be treated.&#xD;
&#xD;
          -  Had microdermabrasion or glycolic acid treatment to treatment area(s) within 1 month&#xD;
             prior to study participation.&#xD;
&#xD;
          -  History of chronic drug or alcohol abuse.&#xD;
&#xD;
          -  Current smokers or have smoked in the last 5 years.&#xD;
&#xD;
          -  History of cosmetic treatments: Skin tightening within last year, injectable filler of&#xD;
             any type within the last year, neurotoxins within the last 3 months, ablative&#xD;
             resurfacing laser treatments, non-ablative, rejuvanative laser treatments in last 6&#xD;
             months, chemical peel, dermabrasion, non-ablative laser or fractional laser&#xD;
             resurfacing of face and neck within the last 4 weeks.&#xD;
&#xD;
          -  History of certain prescription medications (accutane or other retinoids, topical&#xD;
             retinoids, prescription strength skin lightening devices, anti-wrinkle, skin&#xD;
             lightening devices, antiplatelet agents/Anticoagulants, and/or psychiatric drugs).&#xD;
&#xD;
          -  Nursing, pregnant, or planning to become pregnant during study.&#xD;
&#xD;
          -  Current or pre-existing dermatologic diseases on the face or body (psoriasis, rosacea,&#xD;
             eczema, etc.)&#xD;
&#xD;
          -  History of immunosupression/immune deficiency disorders.&#xD;
&#xD;
          -  Current or history of uncontrolled disease such as asthma, diabetes, hyperthyroidism,&#xD;
             etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Stephens, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas J. Stephens &amp; Associates, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stephens &amp; Associates</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>45081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <results_first_submitted>September 30, 2019</results_first_submitted>
  <results_first_submitted_qc>June 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2021</results_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pre-screening was conducted by phone to determine eligibility criteria through and IRB-approved script. Followed by in-clinic screening visits conducted between December 7, 2015 and February 19, 2016.</recruitment_details>
      <pre_assignment_details>Only participants who met eligibility requirements were enrolled into the study and assigned to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SkinPen II</title>
          <description>21 Subjects, 3 SkinPen II treatments to each patient, each one month apart.&#xD;
SkinPen II: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
        </group>
        <group group_id="P2">
          <title>SkinPen Precision</title>
          <description>20 Subjects, 3 SkinPen precision treatments to each patient, each one month apart.&#xD;
SkinPen Precision: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population includes all participants completing the study.</population>
      <group_list>
        <group group_id="B1">
          <title>SkinPen II</title>
          <description>3 treatments with SkinPen II to each patient, each one month apart.&#xD;
SkinPen: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
        </group>
        <group group_id="B2">
          <title>SkinPen Precision</title>
          <description>3 treatments with SkinPen Precision to each patient, each one month apart.&#xD;
SkinPen: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Men and women 18-60 years of age in generally good health were enrolled after satisfying the inclusion and exclusion criteria. Their age, race, and ethnicity were recorded.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Completed Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="11.4"/>
                    <measurement group_id="B2" value="43.8" spread="12.7"/>
                    <measurement group_id="B3" value="44" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Participants were treated and evaluated in Dallas, Texas, USA.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severity of Acne Scars</title>
        <description>Goodman and Baron's Qualitative grading system. Possible scores range from 1 = mild to 4 = severe.</description>
        <time_frame>Baseline, 1 month post treatment, and 6 months post treatment</time_frame>
        <population>The analysis population includes all participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Skinpen ll</title>
            <description>Patients treated with the SkinPen II micro-needling device at 1 day, 30 days and 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Skinpen Precision</title>
            <description>Patients treated with the SkinPen Precision micro-needling device at 1 day, 30 days and 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Acne Scars</title>
          <description>Goodman and Baron's Qualitative grading system. Possible scores range from 1 = mild to 4 = severe.</description>
          <population>The analysis population includes all participants who completed the study.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread=".40"/>
                    <measurement group_id="O2" value="3.10" spread=".31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Month Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread=".68"/>
                    <measurement group_id="O2" value="2.90" spread=".55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-Months Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread=".59"/>
                    <measurement group_id="O2" value="2.70" spread=".57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Goodman and Baron's qualitative acne scar severity scores. Calculated from Wilcoxon signed-rank test. Testing hypothesis is that the mean change from baseline is equal to zero.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.008</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinician's Global Aesthetic Improvement Assessment (CGAIS)</title>
        <description>Clinician's Global Aesthetic Improvement Assessment:&#xD;
minimal score is 1- Very much improved and, maximum score is 5 -Worse: The appearance is worse than the original condition</description>
        <time_frame>1 month post treatment, and 6 months post treatment</time_frame>
        <population>The analysis population includes all participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Skinpen ll</title>
            <description>Patients treated with the SkinPen II micro-needling device at 1 day, 30 days and 60 days.</description>
          </group>
          <group group_id="O2">
            <title>Skinpen Precision</title>
            <description>Patients treated with the SkinPen Precision micro-needling device at 1 day, 30 days and 60 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician's Global Aesthetic Improvement Assessment (CGAIS)</title>
          <description>Clinician's Global Aesthetic Improvement Assessment:&#xD;
minimal score is 1- Very much improved and, maximum score is 5 -Worse: The appearance is worse than the original condition</description>
          <population>The analysis population includes all participants who completed the study.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-Month Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread=".77"/>
                    <measurement group_id="O2" value="3.20" spread=".77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-Months Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread=".77"/>
                    <measurement group_id="O2" value="2.70" spread=".86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis 4 (no change).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Wilcoxen signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Photo Grading of Acne Scar Assessment</title>
        <description>Photo grading of acne scars assessment was done using the following scale [Karnik J. et al, JAAD 2014, 71 (1)]:&#xD;
Grade- Term- Description&#xD;
0 - Clear-- No depression is seen in the treatment area. Macular discoloration may be seen.&#xD;
- Very mild- - A single depression is easily noticeable with direct lighting (deep). Most or all of the depressions seen are only readily apparent with tangential lighting (shallow).&#xD;
- Mild-- A few to several, but less than half of all the depressions are easily noticeable with direct lighting(deep). Most of the depressions see are only readily apparent with tangential lighting (Shallow)&#xD;
3- Moderate-- More than half of the depressions are apparent with direct lighting (deep)&#xD;
4- Severe-- All or almost all the lesions can be seen with direct lighting (deep)</description>
        <time_frame>Day 1 (Baseline), Day 30, Day 60, 1-Month post treatment and 6 Month post treatment</time_frame>
        <population>The analyxed population includes all participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SkinPen II</title>
            <description>21 Subjects, 3 SkinPen II treatments to each patient, each one month apart.&#xD;
SkinPen II: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
          </group>
          <group group_id="O2">
            <title>SkinPen Precision</title>
            <description>20 Subjects, 3 SkinPen Precision treatments to each patient, each one month apart.&#xD;
SkinPen Precision: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
          </group>
        </group_list>
        <measure>
          <title>Photo Grading of Acne Scar Assessment</title>
          <description>Photo grading of acne scars assessment was done using the following scale [Karnik J. et al, JAAD 2014, 71 (1)]:&#xD;
Grade- Term- Description&#xD;
0 - Clear-- No depression is seen in the treatment area. Macular discoloration may be seen.&#xD;
- Very mild- - A single depression is easily noticeable with direct lighting (deep). Most or all of the depressions seen are only readily apparent with tangential lighting (shallow).&#xD;
- Mild-- A few to several, but less than half of all the depressions are easily noticeable with direct lighting(deep). Most of the depressions see are only readily apparent with tangential lighting (Shallow)&#xD;
3- Moderate-- More than half of the depressions are apparent with direct lighting (deep)&#xD;
4- Severe-- All or almost all the lesions can be seen with direct lighting (deep)</description>
          <population>The analyxed population includes all participants who completed the study.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="0.58"/>
                    <measurement group_id="O2" value="2.80" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="0.59"/>
                    <measurement group_id="O2" value="2.78" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="0.53"/>
                    <measurement group_id="O2" value="2.70" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Month post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="0.75"/>
                    <measurement group_id="O2" value="2.68" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-Month post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="0.68"/>
                    <measurement group_id="O2" value="2.35" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated from Wilcoxon signed-rank test. The testing hypothesis is that the mean change from baseline is equal to zero</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Self-Assessment Using SASIS</title>
        <description>Subject self-assessment was completed in 2 steps for self-assessed scar improvement scale (SASIS) and subject global aesthetic improvement scale (SGAIS):&#xD;
Based on a live assessment (subjects were provided with a hand mirror for assessment) of the subject while referring to pre-treatment images.&#xD;
Based on a comparison of pre-treatment images to current post-treatment images. Rating of Acne Scars&#xD;
1-Exacerbation of acne scars 0 No change in the appearance of acne scars&#xD;
1% - 25% improvement in the appearance of acne scars&#xD;
25% - 50% improvement in the appearance of acne scars 3-50% - 75% improvement in the appearance of acne scars 4-75% - 99% improvement in the appearance of acne scars</description>
        <time_frame>One Month Post Treatment, 6 Month Post Treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SkinPen II</title>
            <description>Three treatments using SkinPen II aesthetic microneedling device to each patient, with each treatment spaced one month apart.&#xD;
Aesthetic Microneedling Treatment: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
          </group>
          <group group_id="O2">
            <title>SkinPen Precision</title>
            <description>Three treatments using SkinPen Precision aesthetic microneedling device to each patient, with each treatment spaced one month apart.&#xD;
Aesthetic Microneedling Treatment: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Self-Assessment Using SASIS</title>
          <description>Subject self-assessment was completed in 2 steps for self-assessed scar improvement scale (SASIS) and subject global aesthetic improvement scale (SGAIS):&#xD;
Based on a live assessment (subjects were provided with a hand mirror for assessment) of the subject while referring to pre-treatment images.&#xD;
Based on a comparison of pre-treatment images to current post-treatment images. Rating of Acne Scars&#xD;
1-Exacerbation of acne scars 0 No change in the appearance of acne scars&#xD;
1% - 25% improvement in the appearance of acne scars&#xD;
25% - 50% improvement in the appearance of acne scars 3-50% - 75% improvement in the appearance of acne scars 4-75% - 99% improvement in the appearance of acne scars</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-Month Post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.49"/>
                    <measurement group_id="O2" value="1.65" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-Month Post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="1.23"/>
                    <measurement group_id="O2" value="1.70" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated from Wilcoxon signed-rank test. The testing hypothesis is that the mean score is equal to 0 (no change in the appearance of acne scars).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Self-Assessment Using Global Aesthetic Improvement Scale (SGAIS)</title>
        <description>The following rating scale was used for SGAIS:&#xD;
Rating and Description&#xD;
- Very much improved: Optimal cosmetic result&#xD;
- Much improved: Marked improvement in appearance from the initial condition, but not completely optimal&#xD;
- Improved: Obvious improvement in appearance from initial condition&#xD;
-No change: The appearance is essentially the same as the original condition&#xD;
- Worse: The appearance is worse than the original condition</description>
        <time_frame>1-Month Post Treatment and 6- Month Post Treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SkinPen II</title>
            <description>21 Subjects, 3 SkinPen II treatments to each patient, each one month apart.&#xD;
SkinPen II: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
          </group>
          <group group_id="O2">
            <title>SkinPen Precision</title>
            <description>20 Subjects, 3 SkinPen II treatments to each patient, each one month apart.&#xD;
SkinPen Precision: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Self-Assessment Using Global Aesthetic Improvement Scale (SGAIS)</title>
          <description>The following rating scale was used for SGAIS:&#xD;
Rating and Description&#xD;
- Very much improved: Optimal cosmetic result&#xD;
- Much improved: Marked improvement in appearance from the initial condition, but not completely optimal&#xD;
- Improved: Obvious improvement in appearance from initial condition&#xD;
-No change: The appearance is essentially the same as the original condition&#xD;
- Worse: The appearance is worse than the original condition</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-Month Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="1.06"/>
                    <measurement group_id="O2" value="2.85" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6- Month Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="1.00"/>
                    <measurement group_id="O2" value="2.50" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Calculated from Wilcoxon signed-rank test. Testing hypothesis is that the mean score is equal to 4 (no change).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 6 months</time_frame>
      <desc>Adverse Events (AEs) were defined as any untoward medical occurrence regardless of causal relationship with the test article.</desc>
      <group_list>
        <group group_id="E1">
          <title>SkinPen II</title>
          <description>3 SkinPen ll treatments to each patient, each one month apart.&#xD;
SkinPen ll: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
        </group>
        <group group_id="E2">
          <title>SkinPen Precision</title>
          <description>3 SkinPen treatments to each patient, each one month apart.&#xD;
SkinPen Precision: Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Anthrapod bite</sub_title>
                <description>Brown recluse - inner right thigh</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Erythema (face)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oedema (face)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus (face)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin striae (forehead and both sides of face)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Hitchcock, PhD</name_or_title>
      <organization>Crown Laboratories, Inc.</organization>
      <phone>8883723982</phone>
      <email>THitchcock@crownlaboratories.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

